Items Tagged ‘Stages III-IV Gastric Cancer’

June 28th, 2016

Novel Antibody Improves Survival in Advanced Stomach Cancer

By

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Stomach cancer, […]

View full entry

Tags: 2016, advanced, asco, Gastric Cancer, GEJ cancer, IMAB362, News, Stages III-IV Gastric Cancer, stomach cancer


June 6th, 2016

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer

By

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced gastric cancers. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 […]

View full entry

Tags: 2016, antibody, asco, capecitabine, claudin, Ellence, eloxatin, epirubicin, Gastric Cancer, gastric tumors, IMAB362, longer remission


January 4th, 2016

FDA Clears Marketing Approval for Device to Reduce Hair Loss during Chemotherapy

By

The United States Food and Drug Administration (FDA) cleared for marketing the first cooling cap to reduce hair loss due to chemotherapy. The cooling cap (Dignitana DigniCap Cooling System) is to be used for female breast cancer patients who are undergoing chemotherapy. Certain types of chemotherapy are strongly associated with causing hair loss, whereupon hair […]

View full entry

Tags: alopecia, Breast Cancer, digitana Dignicap Cooling System, fda, Gastric Cancer, hair loss, News, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


September 9th, 2015

Lynparza Improves Overall Survival in High-Risk Gastric Cancer

By

The combination of LynparzaTM (olaparib), and paclitaxel improves overall survival relative to paclitaxel alone in patients with metastatic gastric cancer and low or undetectable levels of a DNA damage response gene known as ATM. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 Americans will be diagnosed with gastric […]

View full entry

Tags: ATM, Gastric Cancer, lynparza, metastatic, News, olaparib, paclitaxel, PARP inhibitor, Stages III-IV Gastric Cancer


August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

By

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients treated with Afinitor plus best supportive care appear to live longer without cancer progression than patients […]

View full entry

Tags: afinitor, everolimus, Gastric Cancer, General Lung Cancer, Lung Cancer, mtor, NET, neuroendocrine tumors, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


May 14th, 2015

Reolysin® Receives FDA Designation for Gastric Cancer

By

The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation (ODD) to Reolysin®, an injectable cancer-killing virus, for the treatment of gastric cancer. Oncolytics Biotech® Inc. recently announced the designation in a press release. The FDA grants ODDs in order to advance the evaluation and development of products that demonstrate promise for […]

View full entry

Tags: cancer killing virus, Gastric Cancer, injectable, News, Reolysin, reovirus, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


February 20th, 2015

U.S. FDA Issues Warning about Certain Type of Endoscope

By

The U.S. Food and Drug Administration (FDA) has issued a Safety Communication about a certain type of endoscope­—specifically the device used in endoscopic retrograde cholangiopancreatography (ERCP). According to the FDA, the device may be difficult to clean effectively and may spread dangerous bacteria among patients. An endoscope is thin, tube-like instrument that’s used to look […]

View full entry

Tags: cancer screening, endoscope, fda, fda warning, Gastric Cancer, News, Recurrent Gastric Cancer, Screening/Prevention Gastric Cancer, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


February 12th, 2015

AMG 337 MET Inhibitor Produces Impressive, Rapid Response in Gastric and Esophageal Cancers

By

AMG 337 is a novel small-molecule MET inhibitor that appears to show promise in the treatment of MET-amplified gastroesophageal junction, gastric, and esophageal cancers. MET inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase. These inhibitors may have therapeutic application in the treatment of various types of […]

View full entry

Tags: AMG 337, Esophageal Cancer, esophagus, Gastric Cancer, gastroesophageal junction, Gastrointestinal Cancer, GI tumors, MET inhibitor, News, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


November 13th, 2014

FDA Approves Cyramza™ in Combination With Paclitaxel for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

By

(CancerConnect) The U.S. Food and Drug Administration(FDA) has approved Cyramza™ (ramucirumab) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma. Cyramza was approved in April 2014 as a single agent for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma refractory to or progressive […]

View full entry

Tags: cyramza, Esophageal Cancer, Gastric Cancer, News, paclitaxel, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


June 26th, 2014

Apatinib Prolongs Survival in Advanced Gastric Cancer

By

Apatinib significantly improved overall survival according to the results of a phase III study presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is the second leading cause of […]

View full entry

Tags: apatinib, Gastric Cancer, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


February 21st, 2014

Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer

By

Ramucirumab significantly improved both progression-free and overall survival, when added to paclitaxel in second-line therapy for metastatic gastric cancer, according to the results of a study presented at the 2014 Gastrointestinal Cancers Symposium. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is […]

View full entry

Tags: Gastric Cancer, News, Recurrent Gastric Cancer, Stages III-IV Gastric Cancer


October 28th, 2013

Ramucirumab Prolongs Survival in Advanced Gastric Cancer

By

The investigational targeted agent ramucirumab prolongs survival in patients with advanced gastric cancer after standard treatments have failed, according to the results of a study published early online in The Lancet. Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is the second leading […]

View full entry

Tags: Gastric Cancer, News, Stages III-IV Gastric Cancer


April 3rd, 2013

Second-Line Docetaxel Improves Survival in Esophageal and Gastric Cancer

By

Second-line treatment with docetaxel improves overall survival of patients with advanced esophageal and gastric cancer, according to the results of a study presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco. The esophagus is a muscular tube that food and liquids pass through on their on their way to the stomach. Each year in […]

View full entry

Tags: Esophageal Cancer, Gastric Cancer, News, Recurrent Gastric Cancer, Stage IV/Recurrent Esophageal Cancer, Stages III-IV Gastric Cancer


September 25th, 2012

Adjuvant Radiochemotherapy Demonstrates Benefit in Gastric Cancer

By

Adjuvant radiochemotherapy provides strong and persistent benefit in patients who have undergone curative gastric resection, according to the long-term results of a study published in the Journal of Clinical Oncology.[1] Gastric cancer refers to cancer of the stomach. Though gastric cancer has a relatively low incidence in the United States, it is the second leading cause […]

View full entry

Tags: Gastric Cancer, News, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer


June 24th, 2011

XELOX May Improve Survival in Gastric Cancer

By

The chemotherapy regimen referred to as XELOX may improve overall survival compared with observation alone in stages II and III gastric (stomach) cancer; however, data are still immature and longer follow-up is necessary. These results were presented in a late-breaking abstract at the 2011 annual meeting of the American Society of Clinical Oncology (ASCO). Gastric […]

View full entry

Tags: Gastric Cancer, News, Stages I-II Gastric Cancer, Stages III-IV Gastric Cancer